logo-loader
viewCytoDyn Inc.

CytoDyn addresses negative claims made by healthcare publication STAT on its coronavirus study

CytoDyn (OTCQB:CYDY) CEO Nader Pourhassan spoke to Proactive, addressing negative claims made by healthcare publication STAT on its coronavirus study. Pourhassan says the company has released what he says are positive results from its coronavirus treatment clinical study, and explains why he thinks healthcare publication STAT has got it all wrong.

Quick facts: CytoDyn Inc.

Price: 4.46 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.32 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to submit request for pre-submission meetings in U.K. for Leronlimab

CytoDyn Inc (OTCQB: CYDY) CEO Nader Pourhassan shared news with Steve Darling from Proactive that the company has started the process of requesting meetings in the U.K. for leronlimab as an HIV treatment as well as for emergency approval of leronlimab for COVID-19 patients with mild-to-moderate...

5 days, 2 hours ago

2 min read